ClinicalTrials.gg
Enrolling by invitationNCT07228065Updated Aug 11, 2026

Fixed-Dose Combinations Pragmatic Randomized Implementation Trial for Blood Pressure Control

An interventional study of Provider nudge and Patient nudge in Hypertension and Primary Care, sponsored by Brigham and Women's Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 53 studies in Hypertension by Brigham and Women's Hospital — 6 open to participants now, 10 under way, none of them phase 3. Hypertension · Brigham and Women's Hospital.

Planned enrollment
11th of 40
720 · median 130
Started
2026
with 2 others
No phase
29 of 53
4 open now
Registered
51st of 53
by date

Among the 53 studies in Hypertension by Brigham and Women's Hospital, this one is the 11th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2026, is one of 29 with no phase, and was the 51st registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 53 studies in Hypertension by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Hypertension by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

The proposed study is an effectiveness-implementation hybrid type II trial designed to evaluate the impact of provider- and patient-directed interventions on FDC use. The trial will test the effectiveness of theory-driven nudges tailored to address provider and patient barriers. All interventions will be pharmacist-driven, with pharmacists delivering information via nudges to providers and via nudges or more intensive interventions (i.e., CPA) to patients. Data to evaluate outcomes will be extracted from electronic health records.

03

Conditions studied

  • Hypertension
  • Primary Care

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with documented hypertension diagnosis
  • had an elevated ambulatory blood pressure reading during the qualifying visit (systolic >140 mmHg or diastolic >90 mmHg
  • have an upcoming scheduled visit
  • have an active prescription for 1 blood pressure lowering medication with a fixed-dose combination (FDC) alternative

Exclusion criteria

Exclusion Criteria:

  • have received a prescription for a FDC in the preceding two years
  • reside in a nursing home
  • have a documented allergy to any FDC components
  • are pregnant
  • preferred language is not English or Spanish, defined as documentation in the EHR indicating a primary language other than English or Spanish, or a documented request for an interpreter in a language other than Spanish
  • have a diagnosis of heart failure or renal failure, given that antihypertensive management in these populations typically requires disease-specific regimens and more frequent treatment adjustments
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
720 participants (estimated)

Study arms

  • Active comparator
    Provider nudge only

    Pharmacists will deliver targeted nudges to providers through clinical decision support integrated into the EHR.

    Behavioral: Provider nudge

  • Experimental
    Provider nudge + Patient nudge

    In addition to provider nudges (Provider nudge only arm), patients will receive pharmacist delivered nudges (e.g., text messages) 1-7 days before the visit to encourage fixed dose combination medications.

    Behavioral: Provider nudge · Behavioral: Patient nudge

  • Experimental
    Provider nudge + Pharmacist Virtual Visit

    In addition to provider nudges (Provider nudge only arm), patients will receive pharmacist counseling and prescribing delivered via virtual encounters after the visit.

    Behavioral: Provider nudge · Behavioral: Pharmacist Virtual Visit

Interventions

  • BehavioralProvider nudge

    Pharmacists will deliver targeted nudges to providers through clinical decision support integrated into the electronic health record (EHR)

  • BehavioralPatient nudge

    Patients will receive pharmacist-delivered nudges (e.g., text messages) 1-7 days before their visit to encourage fixed-dosed combinations

  • BehavioralPharmacist Virtual Visit

    Patients will receive pharmacist counseling and prescribing delivered via virtual encounters after their visit

06

What researchers measure

Primary outcomes

  1. Change in systolic blood pressure

    Data for this outcome will be extracted from electronic health records. The primary effectiveness outcome will be a change in ambulatory systolic blood pressure at 3 months. For patients who do not return within 3 months, their index visit reading will be carried forward.

    Time frame: 6 months

Secondary outcomes

  1. Change in diastolic blood pressure

    Change in diastolic blood pressure from qualifying visit blood pressure reading to the end of the 6-month follow-up, using EHR data

    Time frame: 6 months

  2. Percentage of patients with well-controlled blood pressure

    Percentage of patients who reach blood pressure control defined as \<140/90mmHg

    Time frame: 6 months

  3. PCP level adoption: FDC prescribing; FDC discussion in EHR notes

    Percentage of patients whose PCPs prescribe FDC within 6 months; any intensification at 6 months will also be explored; any FDC documentation in the notes

    Time frame: 6 months

  4. Patient level adoption: FDC adherence (fill)

    Percentage of patients who fill their first FDC prescription within 6 months; filling any intensified prescription within 6 months will also be explored.

    Time frame: 6 months

07

Study locations

1 site
  • Advocate Health
    Milwaukee, Wisconsin 53233, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Apr 2027, 8 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 8 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2025
First posted
Nov 13, 2025
StartActual
Aug 7, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07228065
Responsible party
Julie Lauffenburger (Associate Professor, Brigham and Women's Hospital) — Principal investigator
First posted
Nov 13, 2025
Start date
Aug 7, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion